Halozyme (HALO) Has Compelling Upside Driver in MDASE royalty - Citizens
Tweet Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $92.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
